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The diagnostic guidelines of Alzheimer’s disease (AD) have recently been updated to include brain imaging and
cerebrospinal fluid (CSF) biomarkers, with the aim of increasing the certainty of whether a patient has an ongoing AD
neuropathologic process or not. The CSF biomarkers total tau (T-tau), hyperphosphorylated tau (P-tau) and the 42 amino
acid isoform of amyloid β (Aβ42) reflect the core pathologic features of AD, which are neuronal loss, intracellular
neurofibrillary tangles and extracellular senile plaques. Since the pathologic processes of AD start decades before the first
symptoms, these biomarkers may provide means of early disease detection. The updated guidelines identify three
different stages of AD: preclinical AD, mild cognitive impairment (MCI) due to AD and AD with dementia. In this review,
we aim to summarize the CSF biomarker data available for each of these stages. We also review results from blood
biomarker studies. In summary, the core AD CSF biomarkers have high diagnostic accuracy both for AD with dementia
and to predict incipient AD (MCI due to AD). Longitudinal studies on healthy elderly and recent cross-sectional studies
on patients with dominantly inherited AD mutations have also found biomarker changes in cognitively normal at-risk
individuals. This will be important if disease-modifying treatment becomes available, given that treatment will probably
be most effective early in the disease. An important prerequisite for this is trustworthy analyses. Since measurements
vary between studies and laboratories, standardization of analytical as well as pre-analytical procedures will be essential.
This process is already initiated. Apart from filling diagnostic roles, biomarkers may also be utilized for prognosis, disease
progression, development of new treatments, monitoring treatment effects and for increasing the knowledge about
pathologic processes coupled to the disease. Hence, the search for new biomarkers continues. Several candidate
biomarkers have been found in CSF, and although biomarkers in blood have been harder to find, some recent studies
have presented encouraging results. But before drawing any major conclusions, these results need to be verified in
independent studies.
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The diagnosis of Alzheimer’s disease (AD) can only be
made with certainty after a patient has deceased, by histo-
logical examination of brain tissue at autopsy or, rarely, fol-
lowing brain biopsy. Histopathology should reveal evidence
of the characteristic hallmarks of AD, which are extracellu-
lar accumulations of amyloid β (Aβ) in senile plaques and
intracellular neurofibrillary tangles of hyperphosphorylated
tau (P-tau) [1]. These hallmarks must be seen in sufficient* Correspondence: christoffer.rosen@neuro.gu.se
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reproduction in any medium, provided the ornumbers to confer a pathological diagnosis. This fits with
the idea of a gradual progression and continuum of path-
ology and biomarker changes. Multiple pathologies may
also be present, and the level of each can be critical.
In 1984, a working group established by the National
Institute of Neurological and Communicative disorders
and Stroke and the Alzheimer’s Disease and Related Dis-
orders Association created clinical diagnostic guidelines
of probable AD [2], which were validated against neuro-
pathological diagnosis with a sensitivity and specificity of
around 80 and 70%, respectively [3]. However, the cri-
teria only allowed for making a diagnosis in the demen-
tia stage of the disease, i.e., when the patients were so
severely affected by the disease process that they couldtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and social abilities. Due to advances in research a revi-
sion of the guidelines was made by a new working group
from the National Institute of Aging in 2011 [4]. Now,
imaging and cerebrospinal fluid (CSF) biomarkers have
been implemented to provide evidence of an ongoing
AD pathophysiological process and it is also possible to
make a pre-dementia diagnosis of AD. The included
CSF biomarkers are the total amount of tau (T-tau),
which reflects the intensity of neuroaxonal degeneration,
P-tau, which may correlate with tangle pathology, and
the 42 amino acid isoform of Aβ (Aβ42), which correlates
inversely with plaque pathology [5]. It is well known that
the pathological processes in the brains of AD patients
start more than a decade before the first symptoms are
noticed [6]. The temporal dynamics of biomarker levels
in relation to changes in cognition have been described
in a hypothetical model on the continuum of AD [7]. In
line with this, the revised diagnostic guidelines identify
three different stages of AD: preclinical AD, mild cogni-
tive impairment (MCI) due to AD and AD with demen-
tia. In this review, we will describe the CSF biomarker
characteristics of these three stages, and also give an up-
date on the available data for biomarkers in blood. Im-
aging biomarkers will not be covered.
Biomarkers in preclinical AD
The working group of the National Institute of Aging
was posed with the task of how to define the preclinical
phase of AD [8]. They subdivided this phase into three
separate stages. In the first stage, patients have amyloid
pathology, as defined by positive amyloid on positron
emission tomography (PET) imaging or low CSF Aβ42,Table 1 Summary of preclinical studies on patients with fami
Familia
MCs NCs CSF Aβ42, T-tau, P-tau, Aβ42:Aβ40 ratio or plasm
Aβ42 in MCs vs NCs
88 40 ↓ Aβ42 and ↑ T-tau in CSF, 10 and 15 years before exp
symptom onset, respectively. ↑ Aβ42 in plasma 15 year
before expected symptom onset.
10 10 ↑ Aβ42 and ↑Aβ42: Aβ40 ratio in CSF and ↑ Aβ42 in p
20 years before expected onset of MCI.→ T-tau and→
in CSF.
9 5 ↓ Aβ42, ↑T-tau and ↑P-tau in CSF 17 years before ex
dementia diagnosis.
6 6 ↑T-tau, ↑ P-tau, ↓ Aβ42: Aβ40 ratio in CSF and → Aβ
plasma 11 years before expected AD diagnosis. A tre





↑T-tau, ↑ P-tau in CSF and ↑ Aβ42 in plasma 13 years
expected AD diagnosis.
Aβ = amyloid β; AD = Alzheimer’s disease; CSF = cerebrospinal fluid; MC = mutation
T-tau = total tau.but no signs of neuronal degeneration (normal volumet-
ric magnetic resonance imaging [MRI] of the brain, nor-
mal CSF T-tau levels). In the second stage, neuronal
degeneration is evident and patients have elevated CSF T-
tau or signs of neuronal injury on imaging methods in
addition to positive amyloid markers. To qualify in the
third stage, patients have to experience subtle cognitive
deficits, although not severe enough to meet the criteria
for MCI. To investigate the practical applicability of these
guidelines, Jack et al. applied them to a set of cognitively
normal individuals from a population-based sample [9].
Only imaging, not fluid, biomarkers were used in this
study. After evaluating the results, they found the need for
two additional stage categories: stage 0 and Suspected non-
AD pathophysiology (SNAP). Stage 0 denotes individuals
with no pathological AD biomarkers and no signs of
subtle cognitive impairment. Subjects with SNAP
have normal amyloid biomarkers, but display signs of
neurodegeneration, and could be in the preclinical stage of
a non-AD neurodegenerative process. The proposed cri-
teria are so far intended for research purposes only, and
can provide a common ground to facilitate the search for
biomarkers for preclinical AD. If a disease-modifying treat-
ment for AD is found, it will most likely have the greatest
effect if administered in the early disease stages [10], which
underlines the importance of the work executed by this
working group.
Both cross-sectional and longitudinal studies have
evaluated the association between the core CSF AD bio-
markers and preclinical AD. Their findings are summa-
rized in Tables 1 and 2. The cross-sectional studies have
included patients carrying familial AD (FAD)-causing





A linear model of biomarker levels in relation to time to
expected onset of symptoms was created from
cross-sectional data, and used for comparisons of
biomarker levels at various points in time. According to
this model, CSF Aβ42 seemed to decrease over 25 years




MCs had also elevated plasma Aβ42: Aβ40 ratios. [12]






before ↑ Aβ42:Aβ40 ratios in plasma among MCs were also seen. [15]
carrier; NC = non-carrier; P-tau = hyperphosphorylated tau, Ref = reference;








CSF Aβ42, T-tau, P-tau, Aβ42:Aβ40 ratio
or plasma Aβ42
Comment Ref
55 4 73 8 CSF T-tau was cross-sectionally correlated with
MMSE score. CSF Aβ42 was correlated with future
MMSE and change in MMSE.
There were only women in this study. [16]
61 13 (had a
CDR > 0)
75 3-4 No significant results for Aβ42, T-tau, P-tau in CSF. The main outcome was to predict
conversion from CDR 0 to a higher
CDR. The CSF T-tau:Aβ42 and P-tau:
Aβ42 ratios significantly predicted this.
[17]
51 0 73 3 ↓ Aβ42 in CSF predicted cognitive decline. No
significant results for T-tau or P-tau in CSF.
Cognition was evaluated with memQoL
and MMSE. The combination of CSF
Aβ42 and P-tau predicted cognitive
decline with increased accuracy
compared with Aβ42 alone.
[18]
37 0 73 4.5 ↓ Aβ42 CSF at follow-up correlated with worse
cognition. Individuals with the most substantial
longitudinal decrease of Aβ42 or increase of P-tau
in CSF performed worse on cognitive test than the
others. No significant results for CSF T-tau and
plasma Aβ42.
Cognition was evaluated with ADAS-
cog and AQT.
[19]





3.5 Aβ42 and T-tau in CSF were used for predicting
MCI.
Individuals were dichotomized into
having a high or normal CSF T-tau/
Aβ42 ratio. Individuals with a high ratio
were more likely to develop MCI on
follow-up.
[20]
35 7 85 3 ↓Aβ42 in CSF at baseline in patients that
developed dementia. The CSF Aβ42:Aβ40 ratio
showed a tendency to be lower (p = 0.068) in
individuals that developed dementia.
CSF Aβ40 was lower in patients with
dementia at baseline, but could not
predict dementia in the cognitively
normal.
[21]
127 2, and 11
developed
MCI
60 4 ↓Aβ42, ↑T-tau and ↑ P-tau in CSF among
progressors.
All patients had subjective complaints
at baseline. CSF Aβ42 alone was the
strongest predictor for clinical
progression.
[22]
Aβ = amyloid β; AD = Alzheimer’s disease; ADAS-cog = Alzheimer Disease Assessment Scale–cognitive subscale; AQT = A Quick Test of Cognitive Speed; CDR = Clinical
Dementia Rating; CSF = cerebrospinal fluid; MCI = mild cognitive impairment; memQoL = the memory item of the Quality-of-Life Alzheimer’s disease instrument;
MMSE = mini-mental state examination; P-tau = hyperphosphorylated tau, Ref = reference; T-tau = total tau.
aNot stated specifically for these subgroups.
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markers levels in subjects at risk for carrying an auto-
somal dominant AD mutation [11]. The expected age of
symptom onset was calculated from the participants’
parents’ age at onset of AD symptoms. Linear models
were then created, showing the biomarker levels as a
function of time to expected onset of symptoms in muta-
tion carriers and non-carriers. Mutation carriers had sig-
nificantly elevated levels of CSF T-tau and plasma Aβ42
15 years before expected symptom onset. CSF levels of
Aβ42 were significantly reduced in mutation carriers
10 years before expected onset of symptoms. Another
study that included members of the Colombian
Alzheimer’s Preventive Initiative Registry found that CSF
and plasma Aβ42 levels in young individuals carrying a
specific presenilin 1 (PS1) mutation were significantly in-
creased compared to non-carriers more than two decades
before estimated MCI onset [12]. Studies on cognitively
normal mutation carriers that were closer to the expectedonset of AD have found decreased levels of Aβ42 [13,14],
increased levels of T-tau and P-tau [13,15], and reduced
Aβ42:40 ratio in CSF or increased plasma Aβ42 levels
[15] compared with controls. These studies are
thought to constitute models that are applicable to patients
with sporadic AD as well.
Longitudinal studies have correlated baseline levels of
the core biomarkers in cognitively normal individuals with
decrease in cognitive function or development of MCI or
AD. CSF levels of Aβ42 alone [16] or in combination with
T-tau [17] or P-tau [18] have been associated with future
development of cognitive impairment in individuals that
were cognitively normal at the time of LP. In another
study, healthy older adults were examined and lumbar
punctured at baseline and after a four year follow-up [19].
It was found that low levels of Aβ42 at follow-up were
associated with worse performance on cognitive tests.
Decreasing levels of Aβ42 and increasing levels of P-tau
were also associated with worse cognitive performance.
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Disease Neuroimaging Initiative (ADNI) showed that
individuals with low CSF Aβ42 levels displayed significantly
higher rates of brain atrophy over one year than individuals
with higher Aβ42 levels [23]. Increased T-tau:Aβ42 ratio
[20] or low levels of CSF Aβ42 [21] have been found to
predict conversion to MCI in cognitively normal or AD in
non-demented elder individuals, respectively. One study
on patients with subjective complaints found that CSF
Aβ42 alone was superior to T-Tau, P-tau or a combination
of all three biomarkers in predicting progression to MCI or
AD [22]. However, there are yet no prospective long-term
studies that have investigated whether CSF biomarkers can
predict development of AD in healthy elderly individuals
within 10–20 years. Such studies will be vital to be able to
determine whether the majority of healthy individuals with
low CSF Aβ42 (alone or in combination with tau) will in-
deed develop AD dementia within 1–2 decades.
In this context, it is important to remember that sev-
eral of the longitudinal studies mentioned above are in
fact cross-sectional in respect to the biomarker data,
with one set of baseline biomarker measures correlated
to longitudinal clinical data. This is not the best study
design to examine temporal dynamics in biomarker
changes; the sensitivity of the analytical techniques may
determine when a biomarker appears positive. A very
sensitive method for one marker as compared to a less
sensitive method for another marker may give a false im-
precision that one pathological change precedes the
other. Therefore, we now must validate the hypotheses
and models mentioned above in true longitudinal studies
with repeated biomarker measurements and clinical as-
sessments over time in the same individuals.
Biomarkers in MCI
The risk for patients with MCI to develop AD during a
4.5-year follow-up has been found to be roughly tripled
compared to cognitively healthy controls [24]. However,
MCI is a heterogeneous disorder, and people suffering
from it may progress to other dementias than AD, in-
cluding vascular dementia (VAD), frontotemporal de-
mentia (FTD) and Lewy body dementia (DLB), or
remain relatively stable and decline cognitively as in nor-
mal aging [25]. The combined pattern of low levels of
Aβ42 together with high levels of T-tau and P-tau in
CSF can accurately discriminate incipient AD from pa-
tients with stable MCI [26]. Since the annual progression
rate from MCI to AD is around 10-15% [27], it is im-
portant to have long follow up periods to identify late
converters. One large study found that CSF levels of
Aβ42, T-tau and P-tau among MCI patients could pre-
dict progression to AD with good accuracy after a me-
dian follow-up period of 5.2 years [28]. The combination
of T-tau and Aβ42 gave a sensitivity of 95% and aspecificity of 83%. The study population was evaluated
again after an extended follow-up, now with a median of
9.2 years since baseline [29]. An additional set of pa-
tients from the MCI group had now converted to AD.
The ratio of Aβ42:P-tau at baseline predicted develop-
ment of AD within 9.2 years with sensitivity and specifi-
city around 85-90%. Patients who converted within
5 years had significantly higher levels of T-tau and P-tau
than the patients that converted within 5–10 years, while
the level of Aβ42 was similar. A limitation of that par-
ticular study was however that the cutoff levels for the
CSF biomarkers were established in the same cohort of
patients that was then used to evaluate the diagnostic
performance of the biomarkers to detect incipient AD.
In some other studies, the cutoffs for Aβ42, T-tau and
P-tau have been determined when comparing controls
with patients with AD and then these cut offs have been
applied in cohorts with MCI. Using this approach Hertze
et al. found that different combinations of Aβ42, T-tau
and P-tau could predict AD over 5 years with a sensitiv-
ity of 85-90% and specificity of 71-82% [30]. In a cohort
from the Development of screening guidelines and cri-
teria for predementia Alzheimer’s disease (DESCRIPA)
study, 79% of the patients with amnestic MCI had an ab-
normal CSF Aβ42:T-tau ratio, and this profile was asso-
ciated with progression to AD dementia [31]. A baseline
AD-like profile of CSF T-tau:Aβ42 was present in 89%
of MCI patients from ADNI that developed AD within
one year [32].
A large multicenter study tested the ability of the core
CSF AD biomarkers to predict incipient AD in patients
with MCI [33]. The combination of Aβ42:P-tau ratio
and T-Tau rendered a sensitivity of 83% and a specificity
of 72% for progression to AD. The somewhat low speci-
ficity in this study may be caused by the short follow-up
time of only around 2 years. Also, the biomarker cutoffs
were determined in an independent cohort. This gives a
lower, but truer, diagnostic accuracy. Further, lack of
standardization of pre-analytical and analytical conditions
between the included centers may have contributed.
The potential of the core biomarkers under standardized
settings has proven to be very good. Their diagnostic per-
formance in a homogeneous mono-center population was
excellent, achieving an area under the receiver operating
curve of 0.97 in the discrimination of patients with AD or
patients with MCI who converted to AD against stable
MCI and controls [34].
Indeed, for the biomarkers to be used clinically, stan-
dardization of pre-analytical and analytical factors is
needed. This requires identification of these factors
followed by harmonization between laboratories. The
Alzheimer’s Association quality control program was cre-
ated with the purpose of facilitating the worldwide use of
CSF AD biomarkers in the clinic and research and is
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able assay for CSF Aβ42, T-tau or P-tau [35]. In the test
rounds that have taken place so far, the coefficient of
variation among the contributing labs has been around
15-25% [36]. Currently, only monitoring is conducted,
but further on, active interventions will be crucial. To
that end, several standardization efforts are in progress,
e.g., the Global Biomarker Standardization Consortium,
the CSF-Proteins Working Group of International Feder-
ation of Clinical Chemistry and Laboratory Medicine and
the BIOMARKAPD project of the EU Joint Programme
in Neurodegenerative Disease Research [36].Biomarkers in AD with dementia
CSF levels of T-tau are about 300% higher in AD pa-
tients than control subjects [37]. The biomarker is not
specific for AD and increased levels can be found in the
CSF of patients who have suffered from acute stroke
[38] or head trauma [39], and very high levels are seen
in patients with Creutzfelt-Jakob disease [40]. Since it is
a non-specific marker for axonal and neuronal degener-
ation, non-AD dementias may also give elevated CSF T-tau
levels [41]. In the differential diagnostics against other de-
mentias, P-tau may have a greater value since it is more
AD-specific [42]. Elevated P-tau levels have been found in
patients with AD compared with patients suffering from
FTD and VAD [43], DLB [43,44] and Parkinson disease
with dementia [44]. P-tau differentiated between patients
with AD and patients with FTD and DLB, with specificities
of 92 and 64%, respectively [43]. However, a large study on
patients with AD as well as DLB, FTD and VAD showed
that an AD biomarker profile was present in a substantial
part of the non-AD patients [45]. Potential reasons for this
overlap may be misdiagnosis or the presence of mixed de-
mentias. Future autopsy studies will hopefully shed light
on this issue.
The levels of P-tau in CSF ante mortem correlate with
the amount of neurofibrillary tangles and hyperphos-
phorylated tau in the brain post mortem [46,47]. A study
of cortical biopsies from living patients with normal
pressure hydrocephalus showed a correlation between
the amount of hyperphosphorylated tau in the biopsies
and P-tau levels in CSF [48]. The same study also found
that presence of cortical amyloid plaques was associated
with lower levels of CSF Aβ42. The lower CSF levels of
Aβ42 in AD patients compared with controls are be-
lieved to be caused by its accumulation in senile plaques.
Indeed, autopsy studies have reported correlations be-
tween plaque load and reduced Aβ42 in lumbar CSF
ante mortem [46] and ventricular CSF post mortem [49].
Using positron emission tomography several studies
found an inverse correlation between brain amyloid load
and CSF Aβ42 [50-52].The combination of these biomarkers can accurately
distinguish AD patients from controls, with sensitivity
and specificity over 80% [26,41]. One study that exam-
ined the performance of these biomarkers in AD patients
in different ages found that although diagnostic accuracy
decreased somewhat with age, the positive and negative
predictive values of the biomarkers combined were stable
enough for the biomarkers to be used in old patients
[53]. Their longitudinal stability in AD patients has also
been evaluated. Most studies have found that levels of
Aβ42 and P-tau remain unaltered over time [54-57] while
available data for T-tau is inconclusive [58]. Some studies
report no temporal alteration in T-tau levels in AD pa-
tients, while others have found an increase. However,
high levels of T-tau and P-tau seems to be associated
with increased disease intensity and a more rapid disease
progression [59-61].
Measurement of core AD biomarkers
There are various assays for the three core AD CSF bio-
markers and it is important to bear in mind what they
actually measure. One of the most common assays for
Aβ42 is an enzyme-linked immunosorbent assay (ELISA)
specifically constructed to measure Aβ containing both
the 1st and 42nd amino acids of the protein [62], but
there are also assays that are C-terminally end-specific
but use N-terminal antibodies that allow for measurement
of N-terminally truncated Aβ42 fragments in addition to
Aβ1-42 [63]. Most data suggest that these assays measure
free monomeric Aβ42 but they correlate well with a
selected reaction monitoring-based mass spectrometry
method for total Aβ42 [64]. Tau exists in several isoforms
and may be phosphorylated at different residues. The most
common ELISA for T-tau detects all isoforms of tau, inde-
pendently of phosphorylation state [65]. The two most
common ELISAs for P-tau measure tau that is phos-
phorylated at residue 181 or 231 [66-68], and the diagnos-
tic performance is similar between these assays [43]. A
multiparameter assay based on xMAP® technology was de-
veloped for simultaneous measurement of Aβ42, T-tau and
P-tau [68]. Although it gives different absolute values than
the corresponding ELISAs, correction factors can be used
for direct comparisons.
CSF and imaging biomarkers combined
Even though imaging biomarkers are beyond the scope
of this review we would like to point out some studies
where CSF and imaging biomarkers have been used to-
gether. The combination of CSF and imaging biomarkers
can provide increased diagnostic accuracy compared to
using either modality alone. Shaffer et al. found this to
be the case when using whole-brain MRI, fluorine 18
fluorodeoxyglucose (FDG) PET and CSF T-tau, P-tau
and Aβ42 to predict conversion from MCI to AD [69].
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Aβ42, T-tau and P-tau with MRI-generated regional sub-
cortical volumes and cortical thickness measures gives a
better classification of MCI, AD and controls at baseline
than using either biomarker alone [70]. The prediction
of incipient AD in MCI subjects was also improved by
using the two biomarker modalities together. Vos et al.
found that the CSF Aβ42:T-tau ratio increased the pre-
dictive accuracy for MCI patients with normal and ab-
normal hippocampal volumes on MRI that later
developed AD [71]. MRI only provided increased diag-
nostic accuracy in patients with a normal CSF test.
Other studies have found that CSF T-tau, P-tau, Aβ40
and/or Aβ42 and atrophy of the medial temporal lobe
on MRI provides independent information when dis-
criminating between AD patients and controls [72], and
between patients with stable MCI and MCI patients that
develop AD [73]. Further studies need to elucidate
which imaging methods that are most beneficial to use,
and the correct time point to implement them, in rela-
tion to CSF biomarkers.
Candidate biomarkers
The search for new AD biomarkers may be facilitated by
the core CSF AD biomarkers. By including patients with
signs of an AD pathological process and ensuring that
control subjects lack this profile, future biomarker stud-
ies may be more successful. Results from earlier studies
may, for instance, have been clouded by the presence of
non-symptomatic AD patients in the control groups. A
recent study on the effect size of the major susceptibility
gene for AD, APOE ε4, supports this reasoning; when
disregarding clinical information on patients with cogni-
tive impairment and simply grouping them on the basis
of CSF tau and Aβ markers, the association of APOE ε4
with AD was twice as strong as compared to when clas-
sifying patients according to clinical status [74].
The potential uses for AD biomarkers are many. Be-
sides from diagnostics, CSF biomarkers may be utilized
for prognosis, assessing disease progression, developing
treatments, monitoring treatment effects and studying
disease mechanisms. Several studies have investigated
the AD biomarker potential of various analytes related
to Aβ.
BACE1
For Aβ to be produced, the amyloid precursor protein
(APP) is cut by two different enzymes, β-secretase and
γ-secretase. The major β-secretase in the brain is called
β-site APP cleaving enzyme-1 (BACE1). Several studies
have investigated the levels of CSF BACE1 activity in pa-
tients with MCI and AD, but the results are not univocal.
Three small studies found that patients with AD had in-
creased BACE1 activity compared with non-dementedcontrols [75,76] or patients with other dementias [77]. One
study found higher activity in patients with MCI and de-
mentia due to AD compared with controls [63]. Another
study found significantly elevated BACE1 activity in pa-
tients with MCI but not with AD when comparing with
controls [78]. One study failed to show any differences in
BACE1 activity between MCI and AD patients compared
with controls [79]. However, when patients with a patho-
logic profile of the core AD biomarkers were compared
with controls with a normal biomarker pattern, a signifi-
cant elevation of BACE1 activity was found in the patient
group. The MCI patients contributed the most to this ele-
vation. Finally, a large study did not find any differences in
activity between AD patients and controls [80]. When the
AD patients were stratified into mild and moderate-severe
AD, an increased BACE1 activity could be seen in the
group with mild AD compared the more affected AD pa-
tients and controls. These studies indicate that the activity
of BACE1 may be mildly elevated in the early stages of AD,
but the diagnostic usability of the biomarker seems limited.
It may however prove to be valuable in clinical trials of
BACE1 inhibitors.
sAPPα/sAPPβ
The levels of sAPPα and sAPPβ correlate very well in AD
patients as well as controls [63]. Several studies have failed
to show any differences in the levels of these biomarkers
between AD patients and controls [30,34,63,80,81]. One
study found higher levels of sAPPβ in MCI patients com-
pared with controls [81], and another that MCI patients
that upon follow up developed AD had higher levels of
sAPPβ than patients that didn’t [82]. However, Hertze
et al. found no differences in sAPP levels in MCI patients
with incipient AD compared with stable MCIs or patients
that developed other dementias [30]. Studies that com-
pared patients with MCI or dementia that had a patho-
logic core CSF AD biomarker profile with controls with a
normal profile found that the former group had increased
levels of sAPPα and sAPPβ, but there were large overlaps
between the groups [83-85]. The diagnostic value of
sAPPα and sAPPβ appears limited. Yet, the proteins may
be used for studying effects on the APP metabolism in
clinical trials [5].
Aβ oligomers
Oligomers of Aβ may be more toxic than fibrillar Aβ ag-
gregates [86]. They can inhibit hippocampal long-term
potentiation in vivo [87], and cause abnormal tau phos-
phorylation and neuritic dystrophy [88-90]. A relatively
large number of assay formats to measure Aβ oligomers
in CSF have been published. These papers have shown
that the CSF level of Aβ oligomers is very low, probably
less than 1% of total Aβ levels, and thereby very difficult
to quantify in a reliable manner.
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found in brains [91,92] and CSF [93-96]. However, not
all studies have found altered levels in AD patients versus
controls [97,98], but the latter of these found a negative
correlation between oligomer levels and cognitive status,
indicating a potential use for assessing disease stage in
AD patients. One study found elevated levels of oligo-
mers in human and mouse brains, but not in CSF [99].
Handoko et al. found that CSF oligomer levels in-
creased with age and correlated with levels of T-tau in
cognitively normal older adults. Also, increased levels
were found in cognitively normal subjects with a bio-
marker profile indicating impending AD [100]. Except
for technical difficulties to measure minute amounts of
Aβ oligomers in CSF samples, it is also possible that
different assays measure different variants of Aβ oligo-
mers, which might explain the divergent results. The
studies provide little characterization of what the vari-
ous assays are even measuring.
Other candidate markers
In addition to the amyloid cascade hypothesis, genetics
points to at least three other pathways that may be of
relevance in AD pathogenesis: (i) the innate immune
system, (ii) cholesterol metabolism and (iii) endosomal
vesicle recycling. Better biomarkers for these processes
may give us better tools to assess the importance of ab-
errations in these pathways and to subgroup AD patients
according to which pathway is most abnormal.
Candidate biomarkers may help us to better characterize
the ongoing pathologic processes in the AD brain. One ex-
ample of this is the inflammatory biomarker YKL-40,
which is secreted by activated microglia [101]. Studies have
found increased levels of CSF YKL-40 in AD patients, as a
sign of microglial activation [102-104]. Although Craig-
Shapiro et al. suggested that YKL-40 is secreted by astro-
cytes, data from cell cultures and immunohistochemistry
show that microglia, rather than astrocytes, are responsible
for the main production of YKL-40 [101]. In an experi-
mental setting, Simard et al. provided further insight into
the role of microglia in AD by showing that blood-
derived microglia can prevent the formation of or
eliminate amyloid plaques in transgenic mice [105].
There are several other interesting candidate biomarkers,
such as visinin-like protein-1 [106], neurogranin [107] and
F2-isoprostane [108].
Blood biomarkers
Since blood is more easily accessible than CSF, finding
reliable blood biomarkers for AD is desirable. Due to the
blood–brain barrier, the concentration of brain-derived
proteins in the blood is lower than in the CSF, which
makes this task a challenge. Further, brain-derived pro-
teins are diluted in the large plasma volume and mayalso get degraded. Recent studies point to important dif-
ferences in the regulation of, e.g., tau concentrations in
CSF as compared to blood. In patients with hypoxic
brain injury following cardiac arrest, tau is rapidly re-
leased into the bloodstream but effectively (within
24 hours) cleared in patients with good neurological out-
come [109]. In contrast, CSF tau levels stay elevated for
many weeks following an acute neurological insult [38].
Further, tau levels are clearly elevated in CSF from patients
with Alzheimer’s disease, but less so in the corresponding
plasma samples; measurements of tau in these two com-
partments do not correlate [110].
Many studies have examined the association of plasma
Aβ40 and Aβ42 levels with incipient AD, but the results
are not clear-cut. Some studies have found that elevated
Aβ40 [111,112] or Aβ42 [] levels predicted development of
AD, while others have found the opposite [115] or no asso-
ciations [116,117]. Some studies found that a low Aβ42:
Aβ40 ratio predicted future AD [111,118,119] while others
report an elevated ratio [112,113] or no significant differ-
ence [116] in the group with incipient AD compared with
subjects that didn’t develop AD. Recently, a meta-analysis
over the literature indicated that a low Ab42:Ab40 ratio
could predict development of AD, but no such association
was found for the individual peptides [120]. More research
in the area is needed. Cross-sectional studies that have
compared Aβ levels in AD patients and controls have
mostly found similar group levels [121]. In one study, high
levels of Aβ42 was associated with a more rapid rate of
cognitive decline among AD patients [122]. Recent studies
have, by measuring the levels of several plasma analytes
simultaneously, found biomarker patterns that successfully
differentiated AD patients from controls [123,124] or were
associated with MCI or AD [125]. However, some of these
finding have been hard to reproduce in independent
studies [126,127]. Other studies have found that plasma
analytes such as desmosterol [128], transthyretin [129],
clusterin [130], chitinase 3-like 1 protein [131] and matrix
metalloproteinase 2 [132] may be associated with AD. This
needs to be corroborated in further studies. Several of
these biomarkers have also been associated with AD when
measured in CSF.
Limitations
The major and inherent limitation of fluid biomarkers is
the lack of anatomical precision in the measurements.
Another limitation is the lack of assay standardization.
Different assays for, e.g., Aβ42 correlate but give differ-
ent absolute concentrations of the protein. This prevents
from the use of global reference limits and diagnostic
cut-points. Intense work is currently ongoing to achieve
better assay standardization through the establishment
of reference measurement procedures for tau and Aβ42
and to validate these in multi-center settings [36].
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and experimental work. Although the biomarker CSF
T-tau has been extensively studied there are some basic
aspects that still are unknown. What does steady-state
concentrations of tau among healthy individuals reflect;
is it a low grade neurodegeneration or perhaps normal
neuroaxonal plasticity? It is also not known why some
tau pathologies, e.g. progressive supranuclear palsy,
typically have normal levels of tau and why CSF levels
of tau remain largely unaltered with progression of AD. An
explanation to the latter could be that the levels of tau are
more dependent on the rate of neurodegeneration than the
state, but questions like these warrant translational studies
spanning from models to human disease.
Conclusions
Three core CSF AD biomarkers have been evaluated in a
great number of studies and may provide valuable infor-
mation in all stages of AD. Due to differences in analytic
results between studies and laboratories, standardization
of analytic procedures is essential for the use of these
biomarkers in clinics and in research. Apart from the
core biomarkers, there are several candidate CSF and
blood biomarkers in the pipeline, but they need verifica-
tion in further studies.
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